Mădălina Giurgiu

Mădălina Giurgiu

Auto-generated profile, based on publicly available information

Mădălina Giurgiu

Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2022 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
GTGeorge Tsitsiridis
George Tsitsiridis
RSRalph Steinkamp
Ralph Steinkamp
MGMadalina Giurgiu
Madalina Giurgiu
BBBarbara Brauner
Barbara Brauner
GFGisela Fobo
Gisela Fobo
ARAndreas Ruepp
Andreas Ruepp
The CORUM database has been providing comprehensive reference information about experimentally characterized, mammalian protein complexes and their associated biological and biomedical properties since 2007. Given that most catalytic and regulatory functions of the cell are carried out by protein complexes, their composition and characterization is of greatest importance in basic and disease biology. The new CORUM 4.0 release encompasses 5204 protein complexes offering the largest and most comprehensive publicly available dataset of manually curated mammalian protein complexes. The CORUM dataset is built from 5299 different genes, representing 26% of the protein coding genes in humans. Complex information from 3354 scientific articles is mainly obtained from human (70%), mouse (16%) and rat (9%) cells and tissues. Recent curation work includes sets of protein complexes, Functional Complex Groups, that offer comprehensive collections of published data in specific biological processes and molecular functions. In addition, a new graphical analysis tool was implemented that displays co-expression data from the subunits of protein complexes. CORUM is freely accessible at http://mips.helmholtz-muenchen.de/corum/.

4 May 2023 in Nature Genetics
Verified
Journal Article
Open access
PDF file
RGRocío Chamorro González
Rocío Chamorro González
TCThomas Conrad
Thomas Conrad
MSMaja C. Stöber
Maja C. Stöber
RXRobin Xu
Robin Xu
MGMădălina Giurgiu
Mădălina Giurgiu
AHAnton G. Henssen
Anton G. Henssen
Extrachromosomal DNAs (ecDNAs) are common in cancer, but many questions about their origin, structural dynamics and impact on intratumor heterogeneity are still unresolved. Here we describe single-cell extrachromosomal circular DNA and transcriptome sequencing (scEC&T-seq), a method for parallel sequencing of circular DNAs and full-length mRNA from single cells. By applying scEC&T-seq to cancer cells, we describe intercellular differences in ecDNA content while investigating their structural heterogeneity and transcriptional impact. Oncogene-containing ecDNAs were clonally present in cancer cells and drove intercellular oncogene expression differences. In contrast, other small circular DNAs were exclusive to individual cells, indicating differences in their selection and propagation. Intercellular differences in ecDNA structure pointed to circular recombination as a mechanism of ecDNA evolution. These results demonstrate scEC&T-seq as an approach to systematically characterize both small and large circular DNA in cancer cells, which will facilitate the analysis of these DNA elements in cancer and beyond.

1 March 2022 in Cell Chemical Biology
Verified
Journal Article
Closed access
SJShashi Jain
Shashi Jain
CHCheng Hu
Cheng Hu
JKJerome Kluza
Jerome Kluza
WKWei Ke
Wei Ke
GTGuiyou Tian
Guiyou Tian
DWDieter Wolf
Dieter Wolf

7 August 2024 in Genome Research
Verified
Journal Article
Open access
PDF file
MGMădălina Giurgiu
Mădălina Giurgiu
NWNadine Wittstruck
Nadine Wittstruck
ERElias Rodriguez-Fos
Elias Rodriguez-Fos
RGRocío Chamorro González
Rocío Chamorro González
LBLotte Brückner
Lotte Brückner
AHAnton G. Henssen
Anton G. Henssen
Circular extrachromosomal DNA (ecDNA) is a form of oncogene amplification found across cancer types and associated with poor outcome in patients. ecDNA can be structurally complex and can contain rearranged DNA sequences derived from multiple chromosome locations. As the structure of ecDNA can impact oncogene regulation and may indicate mechanisms of its formation, disentangling it at high resolution from sequencing data is essential. Even though methods have been developed to identify and reconstruct ecDNA in cancer genome sequencing, it remains challenging to resolve complex ecDNA structures, in particular amplicons with shared genomic footprints. We here introduce Decoil, a computational method that combines a breakpoint-graph approach withLASSOregression to reconstruct complex ecDNA and deconvolve co-occurring ecDNA elements with overlapping genomic footprints from long-read nanopore sequencing. Decoil outperforms de novo assembly and alignment-based methods in simulated long-read sequencing data for both simple and complex ecDNAs. Applying Decoil on whole-genome sequencing data uncovered different ecDNA topologies and explored ecDNA structure heterogeneity in neuroblastoma tumors and cell lines, indicating that this method may improve ecDNA structural analyses in cancer.

10 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JLJens Luebeck
Jens Luebeck
EHEdwin Huang
Edwin Huang
FKForrest Kim
Forrest Kim
TLTed Liefeld
Ted Liefeld
BDBhargavi Dameracharla
Bhargavi Dameracharla
VBVineet Bafna
Vineet Bafna
Focal amplifications in the cancer genome, particularly extrachromosomal DNA (ecDNA) amplifications, are emerging as a pivotal event in cancer progression across diverse cancer contexts, presenting a paradigm shift in our understanding of tumor dynamics. Simultaneously, identification of the various modes of focal amplifications is bioinformatically challenging. We present AmpliconSuite, a collection of tools that enables robust identification of focal amplifications from whole-genome sequencing data. AmpliconSuite includes AmpliconSuite- pipeline; utilizing the AmpliconArchitect (AA) method, and AmpliconRepository.org; a community- editable website for the sharing of focal amplification calls. We also describe improvements made to AA since its initial release that improve its accuracy and speed. As a proof of principle, we utilized publicly available pan-cancer datasets encompassing 2,525 tumor samples hosted on AmpliconRepository.org to illustrate important properties of focal amplifications, showing ecDNA has higher copy number, and stronger oncogene enrichment, compared to other classes of focal amplifications. Finally, we illustrate how AmpliconSuite-pipeline enables delineation of the various mechanisms by which ecDNA forms.

13 January 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YBYi Bei
Yi Bei
LBLuca Bramé
Luca Bramé
MKMarieluise Kirchner
Marieluise Kirchner
RFRaphaela Fritsche
Raphaela Fritsche
SKSeverine Kunz
Severine Kunz
AHAnton G. Henssen
Anton G. Henssen
DNA amplifications in cancer do not only harbor oncogenes. We sought to determine whether passenger coamplifications could create collateral therapeutic vulnerabilities. Through an analysis of >3,000 cancer genomes followed by the interrogation of CRISPR-Cas9 loss-of-function screens across >700 cancer cell lines, we determined that passenger coamplifications are accompanied by distinct dependency profiles. In a proof-of-principle study, we demonstrate that the coamplification of the bona fide passenger gene DEAD-Box Helicase 1 (DDX1) creates an increased dependency on the mTOR pathway. Interaction proteomics identified tricarboxylic acid (TCA) cycle components as previously unrecognized DDX1 interaction partners. Live-cell metabolomics highlighted that this interaction could impair TCA activity, which in turn resulted in enhanced mTORC1 activity. Consequently, genetic and pharmacologic disruption of mTORC1 resulted in pronounced cell death in vitro and in vivo. Thus, structurally linked coamplification of a passenger gene and an oncogene can result in collateral vulnerabilities. Significance: We demonstrate that coamplification of passenger genes, which were largely neglected in cancer biology in the past, can create distinct cancer dependencies. Because passenger coamplifications are frequent in cancer, this principle has the potential to expand target discovery in oncology. This article is featured in Selected Articles from This Issue, p. 384